This adds to the 3,000 doses of a similar medicine, RegN-Cov 2, developed by Switzerland’s Roche and US biotech company Regeneron.
Monoclonal antibodies, which are cloned in culture and injected into patients, are seen as highly promising treatments to neutralise the virus, particularly in serious cases of infection. The antibody was discovered by Swiss company Humabs BioMed.
Although the sotrovimab drug has yet to be granted regulatory approval in Switzerland, trials by GlaxoSmithKline show promising results, the government said in a press release on FridayExternal link.
The reservation of 3,000 doses of the drug was made on the recommendation of the Swiss National Covid-19 Taskforce.
The drug is intended as a treatment for at-risk patients who have an increased risk of severe infection.
More
More
Coronavirus: the situation in Switzerland
This content was published on
An overview of the latest Covid-related information in the Alpine nation.
First large-scale alpine solar plant approved in Switzerland
This content was published on
The approval was met with satisfaction by the project's organisers, but it also brings with it a certain amount of pressure.
Medieval squirrels may have ‘helped spread leprosy’
This content was published on
An examination of squirrel remains in the United Kingdom has opened up interesting questions and possibilities in terms of the history of the disease.
Swiss money laundering office registers record number of reports
This content was published on
The Money Laundering Reporting Office Switzerland (MROS) registered a record number of reports of suspicious activity last year.
Two teens accused of planning terror attack released from custody
This content was published on
The Schaffhausen judiciary has released the two teenagers from custody who allegedly planned bomb attacks in Switzerland.
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.
Read more
More
Chair of pharma firm Roche advocates mandatory Covid-19 vaccination
This content was published on
Christoph Franz said he was in favour of compulsory jabs if vaccination coverage rates were insufficient and if there was a social consensus.
This content was published on
Although it has only been in operation since 2000, the Institute of Research in Biomedicine (IRB) has already become a centre of international importance in the field of biomedical research. It has over 300 publications to its credit in academic journals, including Science and Nature. A visitor arriving at the institute for the first…
You can find an overview of ongoing debates with our journalists here . Please join us!
If you want to start a conversation about a topic raised in this article or want to report factual errors, email us at english@swissinfo.ch.